Chris Tame
About Chris Tame
Chris Tame serves as the Vice President and Head of Drug Discovery at Celeris Therapeutics, where he focuses on innovative machine learning techniques for drug development. With a strong background in bioinformatics and extensive experience in the pharmaceutical industry, he has held various leadership roles at organizations such as BenevolentAI and GSK.
Work at Celeris Therapeutics
Chris Tame serves as the VP, Head of Drug Discovery and London Office at Celeris Therapeutics since 2023. In this role, he focuses on designing novel proximity-inducing compounds (PICs™) aimed at treating diseases with significant unmet medical needs. His work involves a patent-filed approach that utilizes active machine learning to predict biomolecular interactions. Tame's expertise in machine learning approaches in bioinformatics and cheminformatics plays a crucial role in target identification, validation, and selection.
Education and Expertise
Chris Tame holds a Master of Chemistry (MChem) with honors from Cardiff University, where he studied from 2003 to 2007. He further advanced his education by obtaining a Doctor of Philosophy (Ph.D.) in Pure and Applied Chemistry from the University of Strathclyde, completing his studies from 2011 to 2014. Tame has expertise in innovative technologies that disrupt drug discovery processes, particularly in the areas of artificial intelligence and targeted protein degradation.
Professional Background
Before joining Celeris Therapeutics, Chris Tame held several significant positions in the pharmaceutical industry. He worked at BenevolentAI as Head of Target Evaluation from 2022 to 2023 and as Discovery Project Leader from 2021 to 2023. Prior to that, he was the Head of Early Discovery Chemistry at BenevolentAI from 2020 to 2023. Tame also spent four years at GSK as Protein Degradation Research Leader and six years as a Medicinal and Synthetic Organic Chemist in the Respiratory Therapy Area.
Previous Experience
Chris Tame's career began with an industrial placement at Chemtura from 2005 to 2006. He gained extensive experience in various roles at BenevolentAI and GSK, where he contributed to drug discovery and development. His work has included the application of machine learning techniques and innovative approaches to enhance target identification and validation.